![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 09, 2019 1:13:15 PM
To all Investors,
* Please be advised we will be changing our company name from Lexington Bioscience to HEART SENTRY as of February 1st 2019. Our stock symbols LNB and LXGTF will remain the same until a change is approved for NASDQ listing.
* There should be no changes to your investment at this time although we can not guarantee that in the near future.
*We have held intensive discussions with various Universities over the last few months and have chosen the University of Florida to conduct the continuation of testing due to the unlimited Senior Citizen population.
*Testing is planned to commence March 1st 2019 with a proposed conclusion by August 2019.
Thereafter submitting our results to the FDA for approval and a speedy initial distribution to major US Healthcare Facilities shortly afterwards.
Thank You for your continued support.
Eric Willis
President Lexington Bioscience (Heart Sentry)
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM